Ness Ziona, Israel, February 23, 2016 – CollPlant Ltd. (TASE:CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products, today announced that it has received its CE Mark for Vergenix™FG, a flowable gel intended to treat chronic and acute wounds. Today’s announcement marks the achievement of a significant milestone and paves the way for sales to begin in Europe in coming months.
Yehiel Tal, Chief Executive Officer of CollPlant, stated, “We are delighted to have received the CE Mark that will enable to market Vergenix™FG in Europe. Vergenix™FG is one of the world’s first medical device containing a recombinant collagen sourced from plants. We are now seeking distributors in Europe in order to set up the necessary sales infrastructure, where initial sales are expected to begin in 2016. “
Vergenix™FG leverages CollPlant’s proprietary tobacco plant-based technology, allowing for the large scale production of recombinant human collagen (rhCollagen). Compared to the standard of care which requires multiple, repetitive treatments, Vergenix™FG requires only a single (one-time) treatment offering greater convenience and cost-effectiveness for both the physician and the patient.
As previously reported, clinical trial results demonstrated that Vergenix®FG is safe and effective for use on human subject and shows excellent wound closure rates.